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Clinical Efficacy of PET/CT Using
68Ga-DOTATOC for Diagnostic Imaging
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Abstract Positron emission tomography/computed tomography (PET/CT) using
68Ga-labelled DOTA0-Tyr3 octreotide (DOTATOC) is one of the diagnostic imag-
ing tools in somatostatin receptor scintigraphy. There have been many studies
demonstrating the clinical usefulness of this diagnostic imaging method, especially
for detecting neuroendocrine tumors (NETs). It often yields clinically relevant
information for determining therapeutic management in NET patients. However,
we have found that the usefulness of the information provided depends on the
clinical situation; for example, it was considered especially helpful when recur-
rence/metastasis was suspected after surgery for histopathologically proven NET.
In addition to NETs, DOTATOC PET/CT sometimes provides useful information
in patients with tumor-induced osteomalacia (TIO), in which fibroblast growth
factor 23 produced by a mesenchymal tumor causes hypophosphatemia, resulting
in osteomalacia. As these mesenchymal tumors frequently express somatostatin
receptors, DOTATOC PET/CT would be expected to detect causative lesions in
TIO. Furthermore, many renal cell carcinomas (RCC) are not FDG avid.
DOTATOC PET/CT could be helpful for detecting unexpected lesions when
recurrence or metastasis is suspected after surgery for RCC. DOTATOC PET/CT
is also able to reveal additional findings even in sarcoidosis, an inflammatory
disease. The clinical value of DOTATOC PET/CT is discussed, based on our
clinical experience.
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23.1 Current Status of Somatostatin Receptor
Scintigraphy in Japan
In diagnostic imaging of cancers, positron emission tomography (PET) using 18F-
labeled fluorodeoxyglucose (FDG) has been widely accepted clinically for staging
and restaging, monitoring therapy response, and detecting unknown primary sites.
However, there are some tumors for which FDG PET/CT does not provide relevant
information owing to their insufficient FDG avidity. Such tumors include well-
differentiated neuroendocrine tumors (NETs), which often cannot be identified as
hypermetabolic areas on FDG PET/CT [1]. A major characteristic of NETs is that
they express somatostatin receptors. For scintigraphy targeting such receptors, a
radiolabeled octreotide, which has high affinity for somatostatin receptors and is
very stable in vivo, has been used in Europe and the United States. Compounds
labeled with 111In or 99mTc are used as tracers for single photon emission computed
tomography (SPECT), and tracers labeled with 68Ga are used for PET.
111In-pentetreotide (OctreoScan) is a commercially available radiopharmaceuti-
cal. It is routinely used clinically in Europe and the United States. However, it is not
currently approved for use in Japan (as of July 2015), although clinical trials were
conducted about the year 2000. Patients must travel to Europe to receive this
examination or personally arrange importation of this radiopharmaceutical to
enable them to undergo scintigraphy in one of several academic institutions. The
number of patients with gastroenteropancreatic NETs is relatively small compared
with the number with other common cancers, but its incidence has been increasing
[2] so that it is becoming a serious issue. In our institution, PET/CT with 68Ga-
DOTATOC for somatostatin receptor scintigraphy has performed since 2011. More
than 300 patients have had this examination here over the last 4 years.
23.2 Usefulness in NET According to Clinical Situation
There have been many reports demonstrating the clinical usefulness of PET/CT
with 68Ga-DOTATOC or other 68Ga-labeled PET tracers in NETs. It has been
reported that it is superior to FDG PET/CT in well-differentiated NET and medul-
lary thyroid cancer [3–5] and scintigraphy using 111In-labeled compounds [6]. Its
diagnostic accuracy, including sensitivity and specificity, is reasonably high (more
than 90 %) according to a few meta-analyses [7, 8]. However, there are some
patients with high hormone levels, indicating the presence of NETs, in whom
DOTATOC PET/CT reveals no additional information.
We investigated the clinical value of DOTATOC PET/CT in relation to the
clinical situation [9]. We divided patients into three groups: groups A, B, and C. In
group A, PET/CT was performed after metastatic NET had been confirmed histo-
pathologically, but the primary tumor had not been identified by other conventional
imaging modalities. In group B, PET/CT was performed to evaluate suspected
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recurrent lesions due to high hormone levels after the patient had undergone
curative surgery for histologically proven NET. Conventional imaging had been
negative before DOTATOC PET/CT. In group C, NET was suspected based on
laboratory data without definitive localization of the primary site by conventional
imaging.
In group A, there were 14 patients who were suspected of having a primary NET
because of pathologically proven liver metastasis (9 patients), nodal metastasis
(3 patients), or bone metastasis (2 patients). In four of the nine patients with liver
metastasis, DOTATOC PET/CT demonstrated positive findings, indicating a
suspected primary tumor in the duodenum (2 patients), jejunum (1 patient), and
pancreatic tail (1 patient) with the maximum standardized uptake value (SUVmax)
ranging from 2.8 to 19.7. DOTATOC PET/CT showed no abnormal findings in the
remaining five patients. In three patients with nodal metastasis, DOTATOC
PET/CT revealed abnormal uptake in the duodenum (1 patient) and jejunum
(2 patients). In two patients with bone metastasis, DOTATOC PET/CT was nega-
tive in one but showed intense focal uptake in the prostate in the other, suggesting
prostate cancer. However, the uptake was found, by biopsy, to be due to benign
prostatic hypertrophy. Thus, a final diagnosis of a gastroenteropancreatic NET was
obtained in 7 of the 14 patients (50 %).
In group B, seven patients underwent surgery for a NET. Except for one patient
with a high insulin level, DOTATOC PET/CT detected ten lesions in six patients
with the SUVmax ranging from 7.9 to 70.1. Two patients had histopathological
confirmation after surgery, and the remaining four patients were followed up with
no surgical treatment. Thus, DOTATOC PET/CT provided additional information
in six of seven patients (86 %). PET/CT imaging in a representative patient with
nodal metastasis is shown in Fig. 23.1.
In group C, a total of 25 patients with suspected NET due to high hormone levels
underwent DOTATOC PET/CT. A pancreatic NET with SUVmax 68.5 was clearly
shown by DOTATOC PET/CT in a patient with a suspected ACTH-producing
tumor, followed by surgical confirmation. In the remaining 24 patients, DOTATOC
Fig. 23.1 A 51-year-old woman with suspected recurrent gastrinoma. Axial CT (a), DOTATOC
PET (b), and fused (c) images are shown. A duodenal gastrinoma was removed by surgery, but
recurrence was suspected because of rising serum gastrin levels. Intense focal uptake around the
lateral segment of the liver is apparent on the DOTATOC PET and fused images (arrows). A
lymph node metastasis was confirmed by surgery
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PET/CT did not provide any additional clinically relevant information. The detec-
tion rate was significantly lower than in the other groups (Fisher’s exact test,
p< 0.01).
We concluded that DOTATOC PET/CT is useful for detecting NET, especially
when recurrence or metastases are suspected because of high hormone levels after
surgery for a primary NET and that it is hardly helpful in patients in whom only the
hormone levels are high and the tumor has not been localized.
It is reasonable that DOTATOC PET/CT would be expected to yield relevant
information when recurrence or metastasis is suspected due to high hormone levels
after surgery for a functioning NET, since the pretest probability is high. In the
patient shown in Fig. 23.1, a small lymph node was visualized retrospectively on
contrast-enhanced CT (figure not shown), but it was difficult to distinguish from a
benign inflammatory node on the basis of size. In addition, it would take time to
confirm the characteristics during follow-up owing to its slow growth. The high
accumulation of DOTATOC in a subcentimeter node is considered a useful finding
for raising the suspicion of recurrence or metastasis after surgery for NET. Con-
versely, among the patients without a history of NET, only in one patient was
DOTATOC PET/CT helpful, and it was negative in the remaining 24 patients.
Some reasons might be considered. Primary sites may be too small to be detected by
imaging modalities. If lesions are extremely small, uptake of DOTATOC could be
underestimated because of the partial volume phenomenon. Also, when the primary
tumor is located in the upper abdomen or alimentary tract, uptake could easily
be influenced by respiratory motion or peristalsis, resulting in underestimation of
uptake. In addition, high hormone levels do not always mean the presence of NET
because hyperfunctioning can cause high hormone levels, e.g., nesidioblastosis in
hyperinsulinemia or G-cell hyperplasia in hypergastrinemia. Furthermore, it has
been reported that somatostatin receptor subtypes 2 and 5 are not well expressed in
many insulinomas [10]. For these reasons, DOTATOC PET/CT may fail to show
the primary tumor.
Peptide receptor radionuclide therapy (PRRT) using 177Lu-labeled or
90Y-labeled octreotide has been used to treat NETs in Europe. To stratify patients
according to their expected response to therapy, somatostatin receptor scintigraphy,
including DOTATOC PET/CT, can be considered. However, we have no sufficient
data so far on this subject because PRRT has not yet been performed in our country.
23.3 Localization of Causative Lesions in Tumor-Induced
Osteomalacia
It is known that DOTATOC PET/CT is useful not only in the imaging of NETs but
also in other diseases. Tumor-induced osteomalacia (TIO) is considered a suitable
target for somatostatin receptor scintigraphy. TIO, which is also known as onco-
genic osteomalacia, is a rare paraneoplastic syndrome. Phosphaturic mesenchymal
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tumors secrete fibroblast growth factor 23 (FGF-23), causing hypophosphatemia
due to suppression of the reabsorption of phosphorus in the proximal renal tubule
and activation of vitamin D synthesis. Consequently, these tumors cause osteoma-
lacia. Total resection of this mesenchymal tumor is essential to achieve complete
cure, but localization of the causative lesions remains a challenge because they are
usually small, slow growing, and are located at peculiar sites. Therefore, somato-
statin receptor scintigraphy can be expected to be useful because these tumors often
express somatostatin receptors [11].
There have been several studies investigating the potential usefulness of somato-
statin receptor scintigraphy for detecting these mesenchymal tumors. As a prelimi-
nary evaluation in our institution, DOTATOC PET/CT has been performed for this
purpose. We analyzed 14 patients (5 men and 9 women, mean age 46 years) with
TIO who underwent DOTATOC PET/CT. All these patients had been suspected of
having TIO due to hypophosphatemia (<2.5 mg/dl) and a high serum FGF-23 level
(49–1,020 pg/ml). Overall, DOTATOC PET/CT showed 12 sites of abnormal
uptake in eight patients. However, three lesions corresponding to bone were
found to be fractured or pseudofractured, i.e., false-positive. Therefore, nine lesions
in seven patients were finally considered to be the cause of the TIO. These lesions
were located in the sphenoid bone, spine, rib, pelvic bone, tibia, and muscles. In the
remaining six patients, DOTATOC PET/CT was negative. One patient is shown in
Fig. 23.2. The serum FGF-23 levels in seven patients with true-positive DOTATOC
PET/CT findings tended to be higher than in patients who had no causative tumor
detected, but the difference was not significant. FDG PET/CT revealed only two
abnormal foci in this population. Our preliminary data suggest that DOTATOC
PET/CT would be a useful noninvasive technique for localizing causative tumors in
patients with TIO and that fractures or pseudofractures caused by osteomalacia can
be a pitfall in interpreting DOTATOC PET/CT images.
This is one of the hot topics in somatostatin receptor scintigraphy. Chong
et al. found that 111In-octreotide SPECT(/CT) was better than FDG PET/CT in
detecting primary mesenchymal tumors causing TIO, with a sensitivity of 95 %
[12]. Jing et al. showed the clinical value of 99mTc-HYNIC-TOC with a sensitivity
of 86 % [13]. Other studies have demonstrated 100 % sensitivity of DOTATATE
PET/CT in detecting causative lesions, although the number of cases is small [14–
16]. In our experience, DOTATOC PET/CT does not always show the causative
lesions, but this noninvasive technique may be considered even when TIO is
suspected and the results of venous sampling are positive, because unexpected
lesions can sometimes be detected by DOTATOC PET/CT.
23.4 Restaging in Renal Cell Carcinoma
Renal cell carcinoma (RCC) may be a target for somatostatin receptor scintigraphy
because some recurrent or metastatic lesions from RCC are not FDG avid [17] and
it has been reported that OctreoScan shows RCC metastasis [18]. At this time,
experience with DOTATOC PET/CT in RCC is limited [19]. We have performed a
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preliminary evaluation of the clinical efficacy of DOTATOC PET/CT in patients
with suspected recurrent RCC after surgery. Seven consecutive patients who had
surgery for histologically proven RCC and who were suspected of having recur-
rence of RCC underwent DOTATOC PET/CT for restaging. We retrospectively
reviewed the PET/CT images and compared available FDG PET/CT findings. In
this investigation, there were 18 recurrent or metastatic lesions in seven patients. Of
the 18 lesions, 13 in six patients with clear-cell carcinoma were clearly shown on
DOTATOC PET/CT, with SUVmax ranging from 2.8 to 23.3 (average 9.7).
Excluding 2 of 13 lesions that were not assessed by FDG PET/CT, only three
lesions were positive on FDG PET/CT. Four lesions were negative on DOTATOC
PET/CT, but positive on FDG PET/CT in a patient with papillary carcinoma.
Fig. 23.2 A 54-year-old man with tumor-induced osteomalacia. Sagittal DOTATOC PET (a) and
fused (b) images are shown. This patient was suspected of having tumor-induced osteomalacia due
to his high FGF-23 level and hypophosphatemia. Intense focal uptake in the lumbar spine is
apparent on the DOTATOC PET and fused images (arrows). The lesion was resected, and the
patient’s phosphorus level returned to normal
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Overall, the sensitivities of DOTATOC PET/CT and FDG PET/CT were 86 % and
67 %, respectively, on a patient basis and 72 % and 56 %, respectively, on a lesion
basis, in our population.
A hypervascular tumor seen in the pancreas in a patient with a history of RCC
may be difficult to differentiate from pancreatic NET and metastasis from RCC
(Fig. 23.3). However, when inconclusive findings are obtained by conventional
imaging, DOTATOC PET/CT would be useful for detecting unexpected additional
metastatic lesions, just as FDG PET sometimes provides useful information if
FDG-avid tumors are present.
23.5 Sarcoidosis
As somatostatin receptors are expressed on activated lymphocytes, it is expected
that sarcoidosis, an inflammatory disorder, may also be visualized. The use of
somatostatin receptor scintigraphy with 111In-pentetreotide in patients with
Fig. 23.3 A 76-year-old man with a hypervascular pancreatic tumor. Contrast-enhanced MR (a),
FDG PET (b), FDG PET/CT (c), DOTATOC PET (d), and DOTATOC PET/CT (e) images are
shown. The contrast-enhanced MR image (a) shows a well-enhanced mass in the pancreatic head
(arrow). The FDG PET image (b) shows no abnormal uptake corresponding to this lesion, but the
DOTATOC PET (d) and the DOTATOC PET/CT (e) images show DOTATOC accumulation in
this tumor (arrows). A pancreatic neuroendocrine tumor and pancreatic metastasis from renal cell
carcinoma was suspected. The final diagnosis was metastatic pancreatic tumor from renal cell
carcinoma. Physiological uptake in a part of pancreas is also seen on the DOTATOC PET images
(arrowheads)
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sarcoidosis was investigated in one study [20]. The somatostatin receptor imaging
was able to demonstrate active granulomatous disease in the patients with sarcoid-
osis, and pathological uptake of radioactivity in the parotid glands during imaging
was correlated with higher serum ACE concentrations. However, the efficacy of
somatostatin receptor imaging in sarcoidosis has not yet been established, and there
are few articles regarding the clinical utility of DOTATOC PET/CT in sarcoidosis.
In our experience, DOTATOC PET/CT reveals a similar or greater number of
lesions than a conventional gallium scan. As compared with FDG PET/CT, uptake
may be lower in involved nodes, but DOTATOC PET/CT could be useful for
evaluating involvement of the myocardium in patients with cardiac sarcoidosis,
because physiological uptake in the myocardium can make FDG PET/CT images
difficult to evaluate. A representative patient with sarcoidosis is shown in Fig. 23.4.
Fig. 23.4 A 65-year-old woman with suspected sarcoidosis. A maximum intensity projection
image (a) and axial CT (b), DOTATOC PET (c), and fused (d) images are shown. Moderate to
intense uptake of DOTATOC is observed in hilar and mediastinal lymph nodes (arrows)
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23.6 Conclusion
DOTATOC PET/CT is a useful imaging modality for detecting NETs, as has been
reported in many articles; however, its efficacy depends on the clinical situation. It
may be helpful especially when recurrence or metastasis is suspected after surgery
of NET, but additional information might not be obtained simply when hormone
levels are high. DOTATOC PET/CT is also considered helpful for identifying
causative lesions in TIO, although fracture or pseudofracture can be a pitfall.
DOTATOC PET/CT could have a clinical impact in restaging of RCC or in
detecting involved lesions in sarcoidosis, but further investigations with more
patients are required.
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